FRONTIER SCIENCE | PUBLICATIONS

The HERA Trial: Cardiac Events at 8 years median follow-up

TITLE OF PUBLICATION

Trastuzumab-associated cardiac events at 8 years of median follow-up in the HERceptin Adjuvant Trial (HERA BIG 1-01)

AUTHORS

Evandro de Azambuja, Marion J. Procter, Dirk J. van Veldhuisen, Dominique Agbor-Tarh, Otto Metzger-Filho, Jutta Steinseifer, Michael Untch, Ian E. Smith, Luca Gianni, Jose Baselga, Christian Jackisch, David A. Cameron, Richard Bell, Brian Leyland-Jones, Mitch Dowsett, Richard D. Gelber, Martine J. Piccart-Gebhart, Thomas M. Suter

PUBLICATION REFERENCE

Journal of Clinical Oncology | Volume 32 | Issue 20 | Pages 2159-2165 | 10 July 2014

READ FULL PUBLICATION

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

NordICC | The Lancet

NordICC | The Lancet

May 5, 2026

Overview The Nordic-European Initiative on Colorectal Cancer (NordICC) study is a multinational, population-based randomized clinical trial set up to investigate the effectiveness of colonoscopy screening on colorectal cancer incidence and mortality in several...

read more
FLAIR | British Journal of Haematology

FLAIR | British Journal of Haematology

Apr 1, 2026

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

read more
ALTTO | ESMO Open

ALTTO | ESMO Open

Oct 24, 2024

Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.

read more
APHINITY | Journal of Clinical Oncology

APHINITY | Journal of Clinical Oncology

Sep 18, 2024

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

read more
OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more